Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Cedar Valley Digestive Health Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06460038CT.gov Tenapanor in Synucleinopathy-Related Constipation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Synucleinopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tenapanor (this asset) | Cedar Valley Digestive Health Center | P2 | CCC · 52 |
| Rasagiline | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2/3 | B |
| Donanemab | Eli Lilly and Company | P2 | CCC |
| PBR-06 | Brigham and Women's Hospital | Unk | D |
| [18F]MNI-1216 | Invicro | Early P1 | NR |
Other indications for Tenapanor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Constipation Disorder | — | P3 | B · 58 |
| Cystic Fibrosis | — | P3 | CCC · 52 |
| Parkinson Disease | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tenapanor in Synucleinopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tenapanor-synucleinopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →